"Novobismol": composition, principle of action, instructions

Updated: 04/23/2021 15:13:42

Expert: Abramova Tsilya

Peptic ulcer disease is one of the leading problems of gastroenterology. According to data, the pathology occurs in 10% of the planet's population. The disease tends to rejuvenate. Gastric and duodenal ulcers are increasingly found in young men and women, as well as in adolescents. The disease is accompanied by abdominal pain, stool disturbances, dyspeptic symptoms, significantly complicates the course of life and leads to complications. Today: an untreated ulcer is a risk factor for developing stomach cancer.

Treatment for peptic ulcer disease is complex and involves taking medications and sometimes surgery. Conservative therapy uses antibiotics, agents to reduce stomach acidity and protect the mucous membrane of the digestive tract. Particular attention is paid to bismuth preparations. They have anti-inflammatory, astringent and reparative effects, and also help get rid of the cause of the disease - the bacteria Helicobacter pylori.

In this article we will look at two bismuth preparations - Novobismol and De-Nol. They contain the same active ingredient, have a common mechanism of action, and have the same indications and contraindications. How the drugs differ and which product to choose - read the article.

It is important to remember: all information is provided for informational purposes only. Bismuth preparations are prescribed by the doctor only after examining the patient and identifying the pathological process.

"Novobismol": description, pharmacodynamics

The drug has an antibacterial effect, therefore it is used to treat ulcerative formations of the digestive system. Available in the form of white, cream-colored tablets. The active ingredient is the organic complex of tripotassium bismuth dicitrate. The composition also includes additional components - magnesium in the form of sterate, corn starch, potassium in the form of polyacrylate and povidone.

The drug is used as an antiulcer medicine with a pronounced astringent effect. In the acidic environment that is present in the stomach, it forms a protective film on erosive and ulcerative formations. Due to this, mucus synthesis increases and protective cellular mechanisms are activated. Therefore, the stomach tissues are better restored, and ulcers stop developing. The product also reduces the effect of the enzymes pepsin and its precursor pepsinogen.

The product remains completely in the stomach and intestines and practically does not enter the bloodstream. A small part of bismuth passes through the intestinal walls and is then completely excreted in the urine.

Novobismol tablets should be stored in normal room conditions at a temperature of no more than 25 degrees Celsius. Avoid exposure to sunlight and keep away from children. The shelf life of the drug is 4 years from the date of production. After this time, the tablets cannot be taken.

Comparison of side effects of De-nol and Ulcavis

Side effects or adverse events are any adverse medical event that occurs in a subject after administration of a drug.

De-nol's side effects are almost the same as those of Ulcavis. They both have few side effects. This implies that the frequency of their occurrence is low, that is, the indicator of how many cases of an undesirable effect of treatment are possible and registered is low. The undesirable effect on the body, the strength of influence and the toxic effect of De-nol are similar to Ulcavis: how quickly the body recovers after taking it and whether it recovers at all.

Indications and contraindications

The drug is indicated for use in the following cases:

• ulcers in the stomach and duodenum at the acute stage;
• chronic gastritis;
• gastroduodenitis in an acute form;
• functional dyspepsia (not due to organic diseases of the digestive system);
• irritable bowel syndrome.

In some cases, tablets cannot be used:

• all trimesters of pregnancy;
• children up to 4 years old inclusive;
• feeding period;
• individual intolerance to any component of the drug;
• severe kidney disorders.

Comparison of ease of use of De-nol and Ulcavis

This includes dose selection taking into account various conditions and frequency of doses. At the same time, it is important not to forget about the release form of the drug; it is also important to take it into account when making an assessment.

The ease of use of De-nol is approximately the same as that of Ulcavis. However, they are not convenient enough to use.

The drug ratings were compiled by experienced pharmacists who studied international research. The report is generated automatically.

Last update date: 2020-12-13 10:32:39

Instructions for use "Novobismol"

Tablets are used by adults and children over 12 years old, 1 tablet three times a day, half an hour before meals. You can also take 2 tablets a day, also half an hour before meals.

For children aged 8-12 years, the dosage is different - 1 tablet twice a day, half an hour before meals. If the drug is indicated for children 4-8 years old, then the daily dosage is calculated based on the ratio of 8 mg per 1 kg of weight. This amount is divided into 2 equal parts and also taken half an hour before meals.

The course lasts from 4 to 8 weeks. However, over the next 2 months it is not recommended to use medications that also contain bismuth.

Comparison of safety of De-nol and Ulcavis

The safety of a drug includes many factors.

At the same time, in De-nol it is quite similar to Ulcavis. It is important where the drug is metabolized: drugs are excreted from the body either unchanged or in the form of products of their biochemical transformations. Metabolism occurs spontaneously, but most often involves major organs such as the liver, kidneys, lungs, skin, brain and others. When assessing metabolism in De-nol, as well as in Ulcavis, we look at which organ is the metabolizing organ and how critical the effect on it is.

The risk-benefit ratio is when the prescription of a drug is undesirable, but justified under certain conditions and circumstances, with the obligatory observance of caution in use. At the same time, De-nol does not have any risks when used, just like Ulcavis.

Also, when calculating safety, it is taken into account whether only allergic reactions occur or possible dysfunction of the main organs. In other matters, as well as the reversibility of the consequences of using De-nol and Ulcavis.

special instructions

The drug can be used during lactation, but in this case it is necessary to stop feeding for the duration of the entire therapy. The general course of therapy should last no more than 8 weeks in a row. It is necessary to carefully follow the dosage according to the instructions. During treatment, you should avoid taking other medications that contain bismuth compounds.

When taking tablets, stool may turn a darker color. In rare cases, the surface of the tongue darkens slightly, which is also normal and does not require additional treatment.

Novobismol does not affect the level of attention, so it can be used while driving a car, as well as by an operator of moving mechanisms.

Comparison of the effectiveness of De-nol and Ulcavis

The effectiveness of De-nol is quite similar to Ulcavis - this means that the ability of the drug substance to provide the maximum possible effect is similar.
For example, if the therapeutic effect of De-nol is more pronounced, then using Ulcavis even in large doses will not achieve this effect.

Also, the speed of therapy - an indicator of the speed of therapeutic action - is approximately the same for De-nol and Ulcavis. And bioavailability, that is, the amount of a drug reaching its site of action in the body, is similar. The higher the bioavailability, the less it will be lost during absorption and use by the body.

Overdose symptoms

If the dosage specified in the instructions is not followed, symptoms of kidney dysfunction may appear. They are reversible - after stopping the use of tablets, kidney function is restored.

If acute symptoms of overdose occur, you must take several tablets of activated charcoal and saline laxatives. A gastric lavage procedure may be necessary. In extreme cases, it is recommended to seek emergency help. In certain situations, the doctor may decide to perform hemodialysis.

Comparison of addiction between De-nol and Ulcavis

Like safety, addiction also involves many factors that must be considered when evaluating a drug.

So, the totality of the values ​​of such parameters as “o syndrome” in De-nol is quite similar to the similar values ​​in Ulkavis. Withdrawal syndrome is a pathological condition that occurs after the cessation of intake of addictive or dependent substances into the body. And resistance is understood as initial immunity to a drug; in this it differs from addiction, when immunity to a drug develops over a certain period of time. The presence of resistance can only be stated if an attempt has been made to increase the dose of the drug to the maximum possible. At the same time, in De-nol the meaning of the “syndrome” is quite small, however, the same as in Ulkavis.

How do antiulcer drugs work?

The mechanism of action of drugs is no different. According to the instructions for use, bismuth tripotassium dicitrate has the following effects:

1. Bactericidal action. The drug is not an antibiotic, but acts against the causative agent of peptic ulcers - Helicobacter pylori. In in vitro studies, bismuth led to a pronounced inhibition of the growth of microorganisms and their subsequent death. The drug works effectively in combination with antibiotics that specifically target Helicobacter. It enhances their effect and helps get rid of pathogenic bacteria. In combination with antibiotics, the effectiveness of eradication therapy increases by 50%.
2. Anti-inflammatory effect. Bismuth suppresses the development of the inflammatory process on the mucous membrane of the stomach and duodenum. In combination with proton pump inhibitors, the drug accelerates recovery.
3. Protective action. In the acidic environment of the stomach, bismuth forms insoluble compounds and forms a protective film on the mucous membrane. It also enhances the production of prostaglandin E, reduces the synthesis of pepsin and pensinogen, and triggers the formation of mucus. Thus, bismuth increases the resistance of stomach cells to the action of gastric juice.
4. Bismuth potassium tricitrate is practically not absorbed in the digestive tract. Only a small amount of the drug enters the systemic circulation. It is excreted mainly through the intestines, a smaller part through the kidneys.

Doctors' opinions and patient reviews

Irina, 48 years old, gastroenterologist, Cherepovets: “De-Nol is a time-tested treatment for gastritis and stomach ulcers. It should be taken only as prescribed by a doctor after confirmation of the diagnosis. The use of bismuth preparations accelerates the healing process of ulcers. I recommend combining treatment with a strict diet. Due to the high cost, this medicine has to be replaced with a cheaper analogue - Ulcavis. There are practically no differences between the products.”

Maria, 35 years old, Krasnodar: “Last year we discovered gastritis caused by Helicobacter pylori infection. The doctor said that eliminating the main cause of its occurrence will help cope with the problem. De-Nol was prescribed, which she took for a month. Signs of gastritis did not appear for almost a year, but this winter, due to stress, the disease worsened again. This time the doctor recommended a cheaper drug - Ulcavis. It also quickly helped to cope with unpleasant symptoms.”

Characteristics of Ulkavis

The drug has the following characteristics:

1. Dosage form and composition. Ulcavis is available in the form of round tablets, coated with a white soluble film. Each contains 120 mg of bismuth dicitrate, potato starch, macrogol, povidone, magnesium stearate, titanium dioxide, potassium polycriline. The tablets are packaged in blisters of 10 pcs. A cardboard pack includes 3, 4 or 6 contour cells.
2. Pharmachologic effect. Bismuth dicitrate inhibits the proliferation of Helicobacter pylori. Ulcavis has astringent and anti-inflammatory effects. Under the influence of gastric juice, the active substance forms insoluble compounds. The substrates released as a result of the reaction create a protective film on the surfaces of ulcerative defects. With regular use of Ulcavis, the production of mucus and bicarbonate increases, the activity of protective mechanisms increases, and tissue resistance to the effects of pepsin is restored.
3. Pharmacokinetics. The active substance is practically not absorbed in the stomach. Small amounts of bismuth may enter the bloodstream. The main part of the drug transformation products is excreted from the body with feces. A small amount of bismuth that penetrates the blood is excreted by the kidneys.
4. Scope of use. The main indication for the use of Ulcavis is gastric and duodenal ulcers caused by the activation of Helicobacter pylori infection. The drug may be included in the treatment regimen for chronic gastritis, gastroduodenitis, irritable bowel syndrome, and dyspeptic disorders.
5. Reception scheme. The dose of the drug is calculated taking into account the weight and age of the patient. Tablets are taken 2-4 times a day, half an hour before meals. The course of treatment should last no more than 8 weeks. Bismuth preparations should not be taken in the next 2 weeks. To eliminate Helicobacter pylori infection, Ulcavis is used in combination with Amoxicillin and Metronidazole.
6. Side effects. The drug may cause digestive disorders such as nausea, vomiting, increased urge to defecate, and constipation. With increased sensitivity to bismuth, itchy skin rashes occur. With long-term treatment, encephalopathy develops, caused by the accumulation of the active substance in the brain tissue.
7. Drug interactions. The pharmacokinetic characteristics of the active substance may change when Ulcavis is used in combination with antacids.

The main indication for the use of Ulcavis is gastric and duodenal ulcers caused by the activation of Helicobacter pylori infection.